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Objectives of the thesis: 
In the past decades, the development of a suitable peroral peptide 
delivery system has been the focus of many pharmaceutical research 
groups.  The recent advancements in biotechnology have lead to 
synthesis, production and purification of a number of peptide and 
proteins such as insulin and octreotide.  Application of these peptides 
in chronic diseases is limited due to their short half life in the blood 
circulation. Hence, numerous injections are required for these 
peptides to be therapeutically effective.  The cost of these injections, 
their inherent challenges in production as well as patient compliance 
issues have lead to major developments in the field of oral drug 
delivery systems. In comparison to the parenteral route, the oral drug 
administration is cheaper, more convenient for the patients and easier 
to manufacture.  However, to develop a suitable peroral delivery 
formulation, a number of hurdles must be overcome. For a peptide 
drug of low bioavailability, the most important challenges in 
developing a successful delivery system are: a) to protect the peptide 
drug from the harsh environment of the stomach; b) to protect the 
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peptide drug against the enzymatic degradation in the small intestine; 
c) to prolong the transit time of the peptide drug in a specific area in 
the gastrointestinal tract; d) to overcome the poor permeability of the 
large, hydrophilic peptide drug across the small intestine. To 
overcome the above obstacles is a challenging task for designing and 
developing a suitable peroral peptide delivery system. Amongst the 
synthetic peptides, insulin has been studied the most due to an 
increase in the number of diabetic patients worldwide.   
In this study, research is described on designing a novel peptide 
delivery system based on CO2 gas empowered delivery (GEDD) 
system. In this system, hydrophilic drugs such as peptides and 
proteins are delivered to the intestinal tract where they are adhered to 
the mucus layer using the mucoadhesive polyethylene oxide (PEO) to 
prolong their residence time at the mucosal surface and trimethyl 
chitosan (TMC) as permeation enhancer will simultaneously trigger 
the opening of the tight junction and drug permeation by the 
paracellular pathway. In the GEDD system, the CO2 gas acts as the 
driving force to push the delivery system to the absorbing membrane 
to form a protective layer around the delivery system to protect it 
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against the enzymatic degradation and also acts as a permeation 
enhancer that mechanically opens the tight junctions. The GEDD 
system was enterically coated with cellulose acetate phthalate (CAP) 
to protect the drug from the acidic pH of the stomach. In this study 
insulin was used as the model drug and an increase in insulin 
permeation using the GEDD system is due to the synergistic effects of 
both the CO2 and TMC as mechanical and chemical enhancers, 
respectively. The GEDD system was tested in sheep’s intestine using 
ex vivo studies and in rabbits for in vivo studies. The ex vivo and in 
vivo studies showed promising results for the future development of 
the system as peroral peptide delivery system.  With respect to 
peptide drug delivery systems, the GEDD systems with its novel 
characteristics may have a promising future in oral peptide drug 
delivery.   
 
 
 
 
 
